STOCKS TELEGRAPH

Author: ST Staff

  • CharePoint Inc. (CHPT) stock surged in the current market; here’s all you need to know about the company

    In the current market, CHPT stock surged by 8.84% to trade at $24.02. CHPT stock previously closed at $22.07. The CHPT stock volume traded at 5.69 million shares.  The average 3-month volume is 5.83M.

    Chargepoint captures the EV charging infrastructure market

    Chargepoint is a fueling network providing company that specifically focuses on the provision and deployment of electric vehicle fuel charging points. The company has provided 90 million sessions up till now across a plethora of charging platforms that exist in North America and Europe. These charging sessions range from the estimate of hundreds of thousands of charging-points that create a session for a car-charging after every 2 seconds approximately.

    CHPT stock consists of the most complete portfolio and profile of an electric vehicle charging company out there. The services and charging solutions include a software-based cloud subscription platform and different applications of charging hardware to allow more variety of flexible options for any sort of scenario in the home, work, business, and commercial lifestyle.

    Chargepoint has entered the EV market space with a portfolio based on EV-based facilitation services. As the competition in the electric vehicle production in the EV market is becoming fierce and the market expands drastically, the attention is catching on towards the subsectors of the EV market like the EV charging infrastructures. The industries and subsectors gain a tailwind from the growth in the EV.

    The future of EV market space and a case for Chargepoint growth

    Bloomberg has projected that the number of EVs sold in 2030 will be 26 million units which is over 1400% increase in the EV units compared to 2020s 1.7 million units. Chargepoint has weathered through the competition and comes out on the other side with a robust growth outlook.

    This outlook is backed up by the financials of the company, which includes the revenue of $146 million for the fiscal year 2021 and shipping of around 31,263 Chargepoint ports. The company is expecting to increase the revenue and number of ports exponentially by FY2026; revenue up to $2.1 billion and ports up to 425,060. The gross margins are also expected to be up to 42% in FY2026 from 24% in FY2020.

    The Biden administration has also announced on Earth Day, the cutting of 50% of emissions over the next nine years by 2030 which makes clean energy stocks like EV more attractive for investors.

    Region-wise, the company is number 1 in North America thanks to the SPAC deal through which it rose to a cash position of $615 million. CHPT stock intends to aggressively expand and operate into the European market where it estimates the cumulative charging infrastructure investment through FY2030 to come in at $60 billion.

    Overall outlook and plans for the CHPT stock

    Three analyst firms have started covering the CHPT stock; earliest since 9th March by Cowen who initiated with a “outperform” rating and a target price of $43. Citigroup initiated on 25th March 2021 and set the rating at “natural” for a target price of $28 while on 16th April 2021, R. F. Lafferty has initiated with a “Buy” rating set to a target price of $29. Overall prospects of the CHPT stock seem attractive to investors for medium-long term investments.

    Furthermore, Chargepoint is collaborating on a national scale with NATSO towards its National Highway Charging Collaborative under which it has a commitment of aggressively scaling its efforts to reach $1 billion in investments by 2030 to provide charging points at more than 4,000 travel plazas and fuel stops across the US. 150 DC fast charging points have been deployed so far.

  • Canaan Inc. (CAN) stock has jumped up in the current trading session; here’s why

    Canaan Inc. (CAN) stock has jumped up in the current trading session; here’s why

    In the current trading session, Canaan Inc. (CAN) stock soared by 0.30% to the price of $13.20 at the time of writing. CAN stock closed the previous session at $13.16. The CAN stock volume traded today is 2.2 million shares. While the average trade volume for the past three months has been 20.19 million. For the past one year, CAN stock has risen by 207.48%. In the past week, the shares jumped by 3.38%. Over the past three and six months, the stock has gained 174.17% and 571.43% respectively. Furthermore, Canaan Inc. (CAN) has is currently trading at $1.91 billion and has an outstanding share of a total of 155.50 million.

    Canaan Inc.’s operation combines Artificial Intelligence and integrated chips

    Canaan Inc. is a computer hardware company that specifically focuses on the research of integrated circuit final systems as well as the manufacturing and selling of the IC final system products. These IC final systems are integrated into the Bitcoin mining and related components while majorly focusing on China as its customer market. The company also has a supply and distribution network of operations for its system products. The company coordinates and collaborates with Northern Data AG for AI development, blockchain expertise and solutions, data-centric solutions.

    The company has the world’s first-ever RISC-V-based edge artificial intelligence (AI) chip the uses of which is applicable to smart-gadget based devices like smart door locks. Canaan is heavily investing in the research and development of advanced and sophisticated technology which include AI architectures and system on chip and chip integrations. AI chip is the core product for the company through which it expands and diversifies its portfolio of product offerings and operations.

    Announcing a partnership with Cathay Tri-Tech

    Canaan Inc has announced today that it is entering into a partnership with Cathay Tri-Tech. The partnership is based on the focus of expanding into the Artificial Intelligence architecture and technological products. This collaboration is specifically for introducing Canaan’s AI facial recognition module to the Japanese market. This AI recognition module utilizes the company’s self-developed Kendryte K210 AI chip.

    Use of Kendryte K210 for Artificial Intelligence-based facial recognition

    Kendryte K210 AI chip is purposefully designed for visual assessment tasks through its processing machine and allows for audio processing as well to some extent. Chips being the core of Canaan’s product; the k210 chip is a compact and low-power consumer which allows it to be a core chip for various ranges of applications that require facial and image recognition. This includes products and machines like smart door locks, elevator systems, vending machines, smart access controls and smart security systems.

    What Cathay gains by collaborating in this partnership?

    Through this partnership, Cathay will be creating edge computing, a C-series of AI products for the first time, and selling it. Cathay also benefits in another way from this deal; it will use Canaan’s AI facial recognition module and IoT product line to develop its own AI integrated line of products known as Artificial Intelligence of Things.

  • LM Funding America, Inc. (LMFA) stock is popping high today: What’s going on?

    LM Funding America, Inc. (LMFA) stock is popping high today: What’s going on?

    LM Funding America, Inc. (LMFA) stock announced the digital assets strategy today after which the LMFA stock price saw a push of 5.45% to reach $1.16 a share at the time of this writing. LMFA stock was green in the previous trading session and went up by 5.77% at closing. Let’s look at current scenarios.

    Digital Assets Strategy:

    LMFA stock announced today that it is planning to purchase digital assets of up to $2 million worth.LMFA will spend this amount in the purchasing of Bitcoin, Ether, and other digital assets that are not securities of this stock. This purchase will cover approximately 10% assets of LM Funding America. Moreover, these assets will provide an alternative to storing value in cash and cash equivalents and will help in the variety of transactions using blockchain technology in the future.

    On January 28, LMFA sponsored LM Acquisition Opportunities, Inc (LMAO) completed the upside initial public offering in which it generated $103.5 million of total proceeds. The management is optimistic that this new digital strategy of LMFA would make LMAO more attractive in terms of a financial technology business with the help of digital assets.

    LM Funding America stock is deeply focused on the development of its transactional capabilities and is planning to announce further developments in the future in terms of purchasing digital assets as well as material vendor relationships.

    Previous News:

    On March 18, 2021, LMFA stock did announce the separate trading of shares of its Class A common stock and warrants under the symbols “LMAO” and “LMAOW” in the Nasdaq Capital Market. The units that are not separated would continue to trade under the symbol “LMAOU”, reported at that time.

    Conclusion:

    It seems that rising momentum was already built by LMFA as it was going high in the previous trading session and today’s news about the purchasing of digital assets have added more hype to the rising stock price of the LMFA. Management is well aware that blockchain technology is the future and responding accordingly. In short, investors need to keep an eye on LMFA stock.

  • SOS stock is plunging in the premarket session; here’s why

    SOS stock is plunging in the premarket session; here’s why

    In the premarket trading, SOS Limited stock plunged by-5.31% to trade at $3.92. SOS stock closed last session at $4.14 which is a -3.94% loss. The company’s stock price oscillated between $4.11 and $4.50today. The share volume traded today was 23.79 million. While the average trading volume for the past 3 months has been 74.95 million. In the past 1 year, SOS stock has jumped up by 314.00%. In the past week, the shares slumped down to -8.61%. In the last three and six months, the stock has increased by 105.97% and 59.85%, respectively. The current value of SOS Limited (SOS) in the market is $773.93 million while its outstanding shares are 186.94 million.

    SOS stock is not yet free from the claims of fraud and lawsuit filings

    Just today, 23rd April 2021, Jakubowitz Law announced that it has also joined the barrage lawsuit claims against SOS by commencing securities fraud class action lawsuit on SOS for the class period 22nd July 2020- 25th February 2021.

    Similarly Pomerantz Law firm has reminded SOS shareholders (who faced losses) to take part in the lawsuit prior to the deadline of 31 May 2021. The list of reminder goes on from law offices of HAGENS BERMAN, Levi &Korsinsky, Frank R. Cruz, Vincent Wong, and others, all of whom had initiated the investigations after the Hidenburg Research tweeted about the company being allegedly involved in fraudulent activities related to claims of cryptocurrency mining operations and location of its office.

    SOS limited had only once fought back the claims by issuing a statement on its website regarding these claims being false accusations only to be made for the economic benefit of the short sellers.

    Context behind SOS’s crypto-mining operations and claims of fraud

    On January 2021, SOS stock announced its crypto mining plans for investing heavily into acquiring mining machines and benefitting from growing investor’s interest in crypto assets. The crypto mining operations are handled by SOS Information Technology (SOS) which is a subsidiary of SOS Limited. Earlier in February the Company announced the acquisition of 5000 crypto mining machines while almost 2 weeks ago it announced the launching of a cloud crypto center established in Hejian County.

    These were later claimed by investigative researchers to be fake news, as covered in our previous article.

    Investigative research had led to finding out that the company had posted several fake and dummy photos as well as inaccurate press releases which called out to be misrepresenting and bogus.

    The Hidenburg Research and Culper Research claim that SOS is an elaborate “pump and dump” scheme that claimed to have bought 15,000 mining rigs on 21 January only to give doctored photos of the crypto miners. Investors fear the risk of investing in SOS stock.

    A respond to the claims?

    SOS Ltd has not responded back to these allegations which have dragged on for few months, by not continuing to do so, the SOS stock is plunging as more and more investors give in to the fear of fraud and overwhelming lawsuits. This is making SOS lose investor’s confidence.

  • Oncova Therapeutics Inc. (ONTX) plunged in the premarket; here’s why

    Oncova Therapeutics Inc. (ONTX) plunged in the premarket; here’s why

    In the premarket, ONTX stock plunged by -3.42% ($0.77) at the time of writing. ONTX stock closed Thursday’s session at $0.80 gaining 21.63%. The stock volume traded is 17.96M shares and the average volume of the past 3 months is 43.60M.

    ONTX stock’s operations and investigational candidates

    Oncova Therapeutics Inc. is a biopharmaceutical company that specifically focuses on the design and development of novel treatments for the treatment of cancers. The company’s investigational candidate product is rigosertib which is currently being studied in the dose-escalation and Phase I expansion for focusing patients with KRAS+ lung adenocarcinoma along with the use of nivolumab. Risosertib is also being focused for the testing in COVID-19.

    The company also has the candidate ON123300 which is a proprietary multi-kinase inhibitor and on 1st April 2021, announced starting ON123300’s dose-escalation and expansion phase I’s second cohort trial in China for HR+ HER2- metastatic breast cancer and refractory cancers. Three patients have been enrolled by ONTX’s corporate partner HanX Biopharmaceuticals for the second cohort.  It is planning to initiate the same trial in USA in the second quarter of 2021.

    First patient has been dosed in the Phase 2 study of Rigosertib

    The company announced on 22nd April 2021, that its investigator-initiated Phase 2 study of Rigosertib has started the first-dosage in first of its patients for targeting recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.

    The study involves 12 patients who will receive Rigosertib in either oral or intravenous form depending upon if the patient has esophageal stricture (recommend intravenous administration) or skin desquamation (recommend oral administration). The period of testing and dosing will be a four-week cycle leading up to 13 cycles. The dosage quantity was oral 1120 mg in a day, halved by morning and afternoon and for intravenous it was a 72-hour infusion with each infusion for 24 hour period consisting of 1800 mg of Rigosertib.

    Full Year Financials review

    ONTX stock released its Full Year 2020 financial results report on 12th March. While the fourth quarter of 2020 in the report did highlight positive news related to clinical and trial approvals, the financials of the full year did perform weakly. The financial results of full-year 2020 may have weakened in comparison to 2019’s result but it is important to keep in mind that many biotech penny stocks had plunged its financial performance in 2020 due to the pandemic, so the financial performance scale is relative for the year 2020 in these stocks.

    Furthermore, the company generated Cash and Cash Equivalents of $19.0 million for the Full-year ending December 31, 2020, and expects its current Cash and Cash equivalents to be sufficient for funding trials and business operations for more than 18 months.

    So what is the outlook for ONTX stock?

    With penny stocks such as ONTX stock, no matter what fluctuations and volatility it reacts to, the fundamentals of the company are relatively a solid point of analysis to look at before investing in it. A factor to keep in mind while looking to buy ONTX stock is the importance of the stock movement trend far outweighs the outlook of ONTX.

    Another fundamental thing to look at for the ONTX is its balance sheet. If the current status of the balance sheet is healthy then it determines that ONTX can carry out its all financial and non-financial obligations while adhering to the investor’s interest.

  • GigCapital3 Inc. (GIK) stock jumped price in the after-market; here’s why

    In the after-market, GigCapital3 Inc. (GIK) shares surged to $9.55 increasing by 9.39% at the time of writing. GIK stock previously closed at $8.73 which is a loss of-3.54%. The stock volume traded today is 0.47 million shares. The average volume of trade for the past 3 months has been 1.56 million. In the past week, GIK stock slumped by -13.31%. GigCapital3 Inc. is currently valued in the market at $252.04 million and has 25.89 million outstanding shares.

    What is GigCapital’s Mentor-InvestorTM methodology?

    GigCapital Global is an investment company that focuses on Private-to-Public Equity (PPE) technology, media, and telecommunications corporations. The company specifically focuses on asset acquisition, recapitalization, and reorganization, and business combinations for one or more businesses.

    The company consists of a team of technology industry corporate executives and private experts. There are also entrepreneurs and operational TMT expert individuals from the public and private markets. GigCapital Global was introduced with the aim to boost and develop the TMT Private to Public Equity companies and become the leading franchise. The operational model for the company is set around a unique Mentor-InvestorsTM model that allows the team at GigCapital to discover TMT companies with high-functioning expert management.

    Announcement of Business Combination between GigCapital3 and Lightning eMotors

    On 12th April 2021, GigCapital3 which is one of GigCapital’s Private-to-Public Equity Corporations had announced that it wanted shareholders to vote for the merger with Lightning eMotors. This voting was to take place on 21st April 2021, in the Special Meeting of Stockholders.

    TheGigCapital3 merger with Lightning eMotors was first announced on 19th November 2020; Lightning eMotors going public via GigCapital3. The news was followed by numerous investigations by law and investigational firms into the fairness of the merger. However, the investigations did not deter eMotors from its operational advancements which included the launching of the new 4th generation Electric Transit Class 3 Van in December 2020 and several orders for its electric line of vehicles.

    GigCapital3 wants to take a piece of the lucrative EV market share. GIK stock sees the potential in innovative penetration of the electric-vehicle producer (Lightning eMotors) into the EV market despite it becoming concentrated and increasingly competitive. The Compound Annual Growth Rate of the EV market (CAGR) according to a report puts it at 41.5% from 2020 to 2027; the market is still flourishing and expanding, so this move is being made at the right time.

    How did GIK’s Special Meeting of Shareholders unfold?

    On 22nd April 2021, GigCapital3 announced that the voting for the merger on 21st April 2021, Special Meeting of Shareholders went successfully as the majority (more than 98%) of voting shareholders approved the merger of the two companies. GIK is expected to submit the 8-K file that holds all the voting results, with the SEC. The finalization of the closing date of the business combination will soon be updated.

    The combined new company will be traded on the New York Stock Exchange under the symbols “ZEV” and “ZEV.WS” respectively. One share of common stock of GigCapital3 will be traded under “ZEV” while three quarters of one will share under the new “ZEV.WS”, leaving no longer GigCapital3 as separate security for trading.

  • Conformis Inc. (CFMS) stock soared in the after-hours trading session; here’s why

    Conformis Inc. (CFMS) stock soared in the after-hours trading session; here’s why

    In the after-hours trading session, Conformis Inc. (CFMS) stock soared by 10.47% to the price of $0.95 at the time of writing. CFMS stock closed the previous session at $0.86 which is a gained 6.12% gain. The CFMS stock volume traded 1.81 million shares. The average daily volume of stock for the past 3 months is 5.41 million. In the past year, CFMS stock soared by 26.47%. In the past week, the stock had gained by 3.74%. In the past three and six months, the CFMS shares had lost -38.13%and gained 9.47% respectively. Conformis Inc. (CFMS) is currently valued in the market at $153.52 million and has a total of 182.43 million outstanding shares.

    Conformis Inc. has a niche product offering in joint replacement implants

    Conformis Inc. is a medical technology company that specifically focuses on joint replacement implants. The company designs, manufactures, and markets these implants and have a product offering which aim to treat the medial, lateral, posterior compartment of the knee; cruciate-retaining product, posterior cruciate ligament substituting product, personalized bicompartmental knee replacement system, and personalized unicompartmental knee replacement product. Knees aren’t the only part the company specializes in replacement; the company also focuses on hip replacement products as well.

    All of the products at Conformis Inc. are customized or personalized to the needs of the patients and also consist of single-use instruments that are required by ambulatory surgical centers and hospitals. Many of the company’s major joint replacement products are patented or proprietary.

    Hitting a milestone in its agreement with Stryker Corporation

    Conformis Inc. has hit another milestone in the project of the joint development agreement with Stryker Corporation. The company announced today – 23rd April 2021, that it has been given approval by the Food and Drug Administration in the USA for the Patent Specific Instrumentation. This PSI was developed by Conformis Inc. for Howmedica under its License and Development Agreement.

    Howmedica is owned by Stryker Orthopaedics as a full subsidiary and it entered into an agreement with Conformis Inc. to work on the Stryker’s Triathlon® Total Knee system with which the now-cleared PSI system is also used. PSI clearance is now the third milestone achieved in this project, despite the testing times of the pandemic, Stryker will now be subjected to delivering $11.0 million to Conformis Inc.

    What is the next step?

    The next step for the company in this partnership is to focus on a long-term distribution agreement for Conformis Inc. to supply the PSI system to meet the demands of Stryker.

    Agreement for the provision of non-exclusive license to Paragon 28

    Previously on 19th April 2021, the CFMS stock had announced another agreement. This time it was a non-exclusive license agreement granted to Paragon 28 subject to a subset of Conformis Inc. US patents for the use of patient-specific instruments technology for Paragon 28’s use of APEX 3DTM Total Ankle Replacement System.

    Growth in licensing agreements and collaborative commercial project is good for CFMS stock

    CFMS stock is performing well due to the company expanding its distinguished medical replacement products and now focusing on the collaboration and partnership for securing long-term deals of its patented technology and products.

  • Why Skechers U.S.A., Inc. (SKX) stock popped high in Thursday aftermarket?

    Why Skechers U.S.A., Inc. (SKX) stock popped high in Thursday aftermarket?

    Skechers U.S.A., Inc. (SKX) announced the first-quarter financial results after which the SKX stock price saw a surge of 7.62% to reach $47.9 a share in the late hours of Thursday on April 22, 2021. SKX was green in the previous trading session and closed with a 0.77% gain. Let’s discuss the earnings results in detail.

    SKX  stock First Quarter Results:

    SKX stock generated  $1.43 billion in revenue from sales in the first quarter of 2021. International sales and domestic sales of the Skechers increase by 20.2% and 8.5% respectively which resulted in the overall increase in the sales up to 15% in the first quarter ended March 31, 2021. The increase in international sales is due to the increase in the wholesales by 23.8% while domestic sales increase is due to direct to consumer as well as eCommerce growth of 143%.

    An increase of margin in both international wholesale and direct-to-consumer segments resulted in an overall increase of 350 basis points in the gross margin to 47.6%. The increase of margin in different segments is attributed to the increased selling price across all channels as well as growth in eCommerce sales.

    SKX stock recorded $157.7 million earnings from the operation which represents the $112.9 million or 252.0% increase over the same period of the prior year.Net earnings for SKX were $98.6 million and $0.63 diluted earnings per share were recorded in the first quarter of 2021.

    Balance Sheet of SKX stock.

    As of March 31, 2020, SKX stock had cash, cash equivalent, and investments of $1.51 billion which represent a decrease of $65.1 million or 4.1% as compared to December 31, 2020. Total inventory increased from $50 million to $1.07 billion in the first three months of 2021 representing the growth of the international wholesale segment.

    Outlook of SKX stock:

    Skechers projected the sales to be between $5.8 billion and $5.9 billion and diluted earnings per share to be between $1.80 and $2.00 for the fiscal year 2021. Sales for the second quarter of 2021 are estimated in the range of $1.45 billion and $1.50 billion and diluted earnings per share in the range of $0.40 and $0.50.

    Conclusion:

    SKX stock has captivated the attention of investors after announcing the strong financial results of the first quarter of 2021. The success of the SKX stock is due to its continued and effective marketing efforts in the United States and the globe. SKX stock is growing day by day and can be a good bet for investors in the long run.

  • Why Skillz Inc. (SKLZ) stock rallied in Thursday’s aftermarket?

    Why Skillz Inc. (SKLZ) stock rallied in Thursday’s aftermarket?

    Shares of Skillz Inc. (SKLZ) were moving high in yesterday’s aftermarket trading session after facing a downtrend of 1.13% in the previous trading session. SKLZ stock price saw a push of 7.24% to reach $17.77 a share in the late hours of Thursday on April 22, 2021. Let’s see the reason behind this rally.

    What’s happening?

    There is no news or press release by the SKLZ stock to explain the rise, no analyst upgrades or upswing targeted per share price of the SKLZ stock to justify the rally. However, Cathie Wood’s ARK Innovation and ARK Next Generation Internet have added 4 million and more than 1 million shares to their portfolio respectively which made the SKLZ stock outperform in the late hours of yesterday because Wood is followed by many people in her stock buying.

    Going back to the previous month on March 17, 2021, SKLZ stock did announce the underwritten public offering of  32,000,000 shares of its Class A common stock. 17,000,000 out of 32,000,000 shares were offered by the Skillz stock itself and the remaining shares were offered by certain stockholders at a public price of $24.00 per share. The underwriters were granted the 30-day option for the purchasing of additional  4,800,000 shares of its Class A common stock.Net proceeds from the offering were intended to support the working capital as well as general corporate purposes of the Skillz stock.

    Financial View of SKLZ stock :

    SKLZ stock will announce its first-quarter financial results on May 4, 2021, after the close of the market. Skillz projected its revenue to be $80 million which beats the analysts’ estimation of the revenue to be in the range between $72.2 million to $79.6 million. In the fourth quarter of 2020, revenues for the SKLZ stock were up by 95% YoY to reach $68 million. Revenue for the full year 2020 reached $230 million which was 92% higher as compared to 2019 and beaten the guidance of $225 million. The revenue for 2021 is projected to be $366 million.

    Conclusion:

    SKLZ stock has been a hot topic among investors as far as market sentiment is concerned. It seems that the Skillz stock is growing at a rapid pace but still it is in its early days of development and much effort is required for further development. In short, investors need to keep an eye on SKLZ stock.

  • The CEL-SCI Corporation (CVM) stock has been rallying for the past week; here’s why

    The CEL-SCI Corporation (CVM) stock has been rallying for the past week; here’s why

    In the current trading session, CEL-SCI Corporation (CVM) stock surged by 20.45% to the price of $24.15 at the time of writing. CVM stock closed Wednesday’s session at $20.05 which is a gain. The stock volume traded today for 6.17 million shares. The shares exchanged hands five times the average volume of trade for the past 3 months. For the past year, CVM stock soared by 75.42%, and the past week it had also jumped 19.42%. In the past three and six months, the stock has gained 38.75%and 33.67% respectively. Furthermore, CEL-SCI is currently valued in the market at $766.11 million and has 40.53 million outstanding shares.

    Biotech Investors are hinging on the success of Multikine phase 3

    CEL-SCI stock rallied up to 45% this week. The boost is coming due to the gathering of results for the advancement in the phase III trial of its flagship investigational product Multikine.

    On similar news related to Multikine, the company had seen a whopping gain of 82% in the month of January (on 26th) which was correlated with the WallStreetBets rally. Multikine is the only late-stage candidate of CVM stock and the reason behind the surge was the tweet by Geert Kersten – CEO of CEL-SCI which hyped up news about Multikine Phase III data’s release.

    However, the news of the release of data had dragged on even passing the month of February, in which the Kerstentold the investors to keep their head high for the data and have confidence in the stock. Now the hype is aired around the full data analysis readout for the clinical study of immunotherapy. Success of this lead investigative product will lead to a life-changing course of action for patients with squamous cell carcinoma in the head or the neck.

    Where will the success of Multikline lead the company?

    The success of phase III Multikline will move the company to a phase where it can commercialize this treatment and boost the value of the CVM stock. Furthermore, the company will become an attractive buyout candidate for big pharma companies waiting to gain the benefits of its future potential.

    CES-SCI’s lead product offering and operational background

    CEL-SCI Corporation is a biotechnology company that specifically focuses on the design and development of novel treatments that are offered to target the demands and unmet needs of patients with certain diseases. The biotech company aims to develop immunotherapies for the treatment of infectious diseases as well as cancer. The leading investigational immunotherapy of CEL-SCI is Multikine. Multikine is being developed for the treatment of head and neck cancer. The immunotherapy is currently under clinical phase III trial.

    CEL-SCI has also created a T-cell modulation procedure that can trigger the immune system to fight bacterial, parasitic and viral infections. The process is done by the system known as LEAPS which stands for Ligand Epitope Antigen Presentation System. LEAPS also focuses on the countering of autoimmune diseases, cancer, and allergies. The company uses this LEAPS system for a different platform which includes the treatment of rheumatoid arthritis and even a product candidate for coronavirus.